Committed to providing comprehensive support for global drug development

As a key GPCR, ADRA1A is abundant in prostate smooth muscle, prefrontal cortex and blood vessels. It signals through Gαq/11-PLCβ to regulate smooth muscle contraction, blood pressure and memory consolidation. A validated BPH target, its antagonists relieve urinary dysfunction. ADRA1A variants relate to PTSD risk, and antagonists block pathological memory reconsolidation (Phase II). It also modulates prostate cancer angiogenesis for combination immunotherapy. Our ADRA1A stable cell lines have been validated in calcium mobilization assays to support your drug discovery programs.